NCT06434649Active, not recruiting
Posterior Extra-fascial RARP in Intermediate or High Risk Prostate Cancer
Application of the Extra-fascial Robot Assisted Radical Prostatectomy Via the Posterior Approach in Intermediate or High Risk Patients: a Prospective, Multicenter, Double-blind, Randomized Controlled Study
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
This study was designed as a prospective, multicentre, double-blind, randomised controlled clinical trial. It aims to investigate the feasibility and safety of the posterior approach extrafascial technique and the anterior approach extrafascial technique in robot-assisted radical prostatectomy (RARP) for intermediate- and high-risk prostate cancer patients, to compare the oncological prognosis, functional prognosis, and safety of the two techniques in intermediate- and high-risk prostate cancer patients, and to provide evidence-based medical evidence for the choice of surgical treatment modality for intermediate- and high-risk prostate cancer patients.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 118 (estimated)
- First submitted
- 10 May 2024
- Start date
- 1 Nov 2025
- Primary completion date
- 1 Oct 2026
- Lead sponsor
- Ning Xu
- Diseases
- Prostate cancer
- NCT number
- NCT06434649
What you commit to
- Study type: Interventional
- Planned participants: 118
- From 1 Nov 2025 to the primary completion date, 1 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- comorbidities with other malignancies;
- patients with severe underlying diseases such as severe pulmonary insufficiency who could not tolerate the surgery;
Age
- life expectancy \<10 years;
Other
- uncorrected coagulation dysfunctions;
- patients or family members who did not accept radical prostatectomy.
Who the study is looking for
- intermediate- and high-risk prostate cancer patients assessed by comprehensive clinical evaluation;
- prostate volume \<80 ml;
- life expectancy of patients \>10 years;
- patients sign the "informed consent";
- Routine preoperative examination has been improved (chest CT, electrocardiogram, and color Doppler echocardiography), and there is no serious basic disease. After clinical evaluation, it can tolerance robot-assisted radical prostatectomy (RARP).
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| first hospital affiliated of Fujian medical university Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.